Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: The other side of the coin

Journal of Clinical Oncology

Volumn 29, Issue 28, 2011, Pages 3835-3837

  Garassino, Marina Chiara ^a   Marsoni, Silvia ^b   Floriani, Irene ^c  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b Southern European New Drugs Organization Foundation   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PEMETREXED;

CANCER CHEMOTHERAPY; CANCER RELAPSE; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; SMOKING;

EID: 80053628045     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.7847     Document Type: Letter

References (9)

1. Keedy VL, Temin S, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127, 2011
2. D'Angelo SP, Pietanza MC, Johnson ML, et al: Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29:2066-2070, 2011
3. Paik PK, Arcila ME, Fara M, et al: Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046-2051, 2011
4. Bunn PA Jr, Doebele RC: Genetic testing for lung cancer: Reflex versus clinical selection. J Clin Oncol 29:1943-1945, 2011
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
6. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
7. Ciuleanu T, Stelmakh L, Cicenas S, et al: Erlotinib versus docetaxel or pemetrexed as second line therapy in patients with advanced non small cell lung cancer and poor prognosis: Efficacy and safety results from phase III TITAN study. Presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, December 9-11, 2010 (abstr LBOA5)
8. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
9. Maruyama R, Nishiwaki Y, Tamura T, et al: Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26:4244-4252, 2008